Clinical trials: Patients with Advanced Solid Tumors
Cancer
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients
A phase 1 dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of PF-04691502 in adult cancer patients with solid tumors.
- Trial name
- NCT00927823
- Testing
- PF-04691502
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Advanced Solid Tumors
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
- Trial name
- NCT06715124
- Testing
- QTX3544, Cetuximab
- Where
- 10 sites in United States
- Volunteers
- 237 people
- Sponsor
- Quanta Therapeutics
Solid Cancer
A Study of HS-20124 in Patients with Advanced Solid Tumors
HS-20124 is a novel DAR-8 antibody-drug conjugate （ADC） targeting CDH6. In preclinical studies, it inhibited tumor cell growth expressing CDH6 in vitro and in vivo.
- Trial name
- NCT06763159
- Testing
- HS-20124 (Phase Ia：Dose escalation ), HS-20124 (Phase Ib: Dose expansion)
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Hansoh BioMedical R&D Company
Advanced Malignant Solid Neoplasm, ALK Positive
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
This phase I trial studies the side effects and best dose of ceritinib and combination chemotherapy in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled…
- Conditions
- Advanced Malignant Solid Neoplasm, ALK Positive, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer
- Trial name
- NCT02227940
- Testing
- Ceritinib, Cisplatin, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Roswell Park Cancer Institute
Solid Malignancies
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
This study is being conducted to assess the safety, tolerability and PK of AZD1480 in patients with advanced solid malignancies.
- Trial name
- NCT01112397
- Testing
- AZD1480
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Adult Solid Neoplasm, Lung Carcinoid Tumor
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of trebananib and temsirolimus when given together in treating patients with solid tumors that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Solid Neoplasm, Lung Carcinoid Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01548482
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus
- Where
- 3 sites in Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
This phase I trial is studying the side effects and best dose of R-(-)-gossypol acetic acid when given together with cisplatin and etoposide in treating patients with advanced solid tumors or extensive stage small cell lung…
- Trial name
- NCT00544596
- Testing
- R-(-)-gossypol acetic acid, cisplatin, etoposide
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
- Trial name
- NCT02301117
- Testing
- TAS-102
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 43 people
- Sponsor
- Taiho Oncology, Inc.
Cancer
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
This study will aims to determine the maximum tolerated dose of CGC-11047 when used in individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or cisplatin or 5-flurouracil or sunitinib in one of 7…
- Trial name
- NCT00705874
- Testing
- CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 172 people
- Sponsor
- Progen Pharmaceuticals
Advanced Cancer
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.
- Trial name
- NCT07605962
- Testing
- UI-102
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- United Immunity, co., Ltd.
Solid Tumors, Lymphomas
A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
TSR-011 is a potent small molecule inhibitor of tyrosine kinases involved in cancer, including: 1. Anaplastic lymphoma kinase (ALK) 2.
- Trial name
- NCT02048488
- Testing
- TSR-011
- Where
- 15 sites in United States, Poland and 3 more
- Volunteers
- 72 people
- Sponsor
- Tesaro, Inc.
Advanced Solid Tumors
A Trial of TAS-114 in Combination With S-1
A Phase I, Open-Label, International, Multicenter, Non-Randomized, Dose-Escalating Safety, Tolerance and Pharmacokinetic Study of Oral Administration of TAS-114 in Combination with S-1 in a Twice Daily Schedule for 14 Days in…
- Trial name
- NCT02454062
- Testing
- TAS-114, S-1
- Where
- 5 sites in Belgium, France and 2 more
- Volunteers
- 120 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Solid Tumor
Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.
HS-20105 is a novel antibody-drug conjugate (ADC) targeting Trop-2. This first-in-human trial is aimed to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics (PK), safety and…
- Trial name
- NCT06144723
- Testing
- HS-20105
- Volunteers
- 402 people
- Sponsor
- Hansoh BioMedical R&D Company
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
This phase I/II trial identifies the side effects and best dose of pevonedistat when given together with pembrolizumab in treating mismatch repair deficiency (dMMR)/high-frequency microsatellite instability (MSI-H) solid tumor…
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04800627
- Testing
- Pembrolizumab, Pevonedistat
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
6MW3511 in Patients With Advanced Solid Tumor
This is a phase I/II , open-label, multicenter single arm study designed to evaluate the safety, tolerability, pharmacokinetic (PK), and immunogenicity of 6MW3511.
- Trial name
- NCT05524194
- Testing
- Intravenous Infusion
- Volunteers
- 272 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Lymphoma, Small Intestine Cancer
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced solid…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004002
- Testing
- bortezomib
- Where
- 5 sites in United States
- Sponsor
- NYU Langone Health
Neoplasms
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 therapy in terms of drug-related adverse events when combined with a platinum therapy (cisplatin or carboplatin).
- Trial name
- NCT00969761
- Testing
- BI-6727, BI 6727
- Where
- 2 sites in Belgium
- Volunteers
- 61 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor of Epithelial Origin, Gastric Cancer
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability profile including the dose limiting toxicity of AbGn-7 in patients with chemo-refractory advanced solid tumor of epithelial origin, and of AbGn-7 in…
- Trial name
- NCT01466569
- Testing
- AbGn-7
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 13 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ALK rearrangement.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439266
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.